tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 6, 2000, Pages 770-775

  Nishida, Motoi ^a,b   Matsuno, Hiroyuki ^a   Kozawa, Osamu ^a   Ueshima, Shigeru ^b   Matsuo, Osamu ^b   Collen, Désiré ^c   Uematsu, Toshihiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

GPIIb IIIa; Platelets; Thrombus; tPA; Xa inhibitor

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CAROTID ARTERY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; HEMOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0033659684     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200012000-00013     Document Type: Article

References (35)

1. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
2. Thrombosis and the pharmacology of antithrombotic agents
3. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors
4. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats
5. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis
6. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model
7. Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation
8. Shear-induced platelet aggregation is inhibited by in vivo infusion of an antiglycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty
9. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein
10. Basic and clinical aspects of fibrinolysis and thrombolysis
11. The cell biology of the plasminogen system
12. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
13. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model
14. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator
15. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model
16. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig
17. Fibrinolytic factors play a different role on the development or lysis of thrombus formation
18. Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom
19. Physiological consequences of loss of plasminogen activator gene function in mice
20. Thrombin receptor expression in normal and atherosclerotic human arteries
21. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
22. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood
23. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
24. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa
25. Inhibition of integrin function by a cyclic RGD-containing peptide
26. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist
27. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster
28. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis
29. Comparison of the antithrombotic effects and bleeding risk of fractionated ATA and GPIIb/IIIa antagonist, GR144053 in a hamster model of stenosis
30. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction
31. Fibrinolysis inhibits shear stress-induced platelet aggregation
32. Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm
33. Growth factor control of extracellular proteolysis
34. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells
35. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions